|
Oct 3
|
Invaio Sciences Appoints André Andonian as Chairman of the Board of Directors
|
|
Oct 1
|
Foghorn Therapeutics to Participate in the BMO Oncology Summit
|
|
Jul 29
|
Institutional investors own a significant stake of 36% in Foghorn Therapeutics Inc. (NASDAQ:FHTX)
|
|
May 9
|
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Just Reported, And Analysts Assigned A US$11.67 Price Target
|
|
May 7
|
Foghorn Therapeutics First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
|
|
May 6
|
Foghorn Therapeutics Q1 2024 Earnings: Misses Analyst Revenue Projections Amidst Strategic ...
|
|
May 6
|
Foghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Misses Revenue Estimates
|
|
May 6
|
Foghorn Therapeutics Provides First Quarter 2024 Financial and Corporate Update
|
|
Apr 16
|
Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Kristian Humer as Chief Financial Officer
|
|
Apr 9
|
Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs
|
|
Apr 9
|
Foghorn Therapeutics (NASDAQ:FHTX) Is In A Good Position To Deliver On Growth Plans
|
|
Apr 5
|
Foghorn Therapeutics to Participate in Needham’s 23rd Annual Virtual Healthcare Conference
|
|
Apr 2
|
Does Foghorn Therapeutics (FHTX) Have the Potential to Rally 105.75% as Wall Street Analysts Expect?
|
|
Mar 26
|
Foghorn to Host Conference Call and Webcast on Pipeline of Potential First-in-Class Medicines in Conjunction with the 2024 AACR Annual Meeting
|
|
Mar 13
|
Foghorn Therapeutics Inc. (FHTX) Upgraded to Buy: Here's What You Should Know
|
|
Mar 13
|
Wall Street Analysts Predict a 124.31% Upside in Foghorn Therapeutics Inc. (FHTX): Here's What You Should Know
|
|
Mar 7
|
Foghorn Therapeutics Inc. (FHTX) Reports Q4 Loss, Tops Revenue Estimates
|
|
Mar 7
|
Foghorn Therapeutics Provides Financial Update for 2023 and 2024 Strategic Outlook
|
|
Mar 5
|
Foghorn Therapeutics to Present New Preclinical Data at 2024 AACR Annual Meeting, Reflecting Advances with Multiple Potential First-in-Class Medicines, including the Selective Inhibitor of BRM, FHD-909
|
|
Feb 28
|
Silence Therapeutics PLC Sponsored ADR (SLN) Soars 6.4%: Is Further Upside Left in the Stock?
|